Anika Therapeutics Analyst Ratings
Anika Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2022 | 13.26% | Barrington Research | → $31 | Upgrades | Market Perform → Outperform |
| 10/14/2022 | -5.01% | Stephens & Co. | → $26 | Reinstates | → Equal-Weight |
| 03/09/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 11/16/2021 | 100.95% | Stephens & Co. | → $55 | Initiates Coverage On | → Overweight |
| 07/16/2021 | 68.07% | UBS | → $46 | Initiates Coverage On | → Neutral |
| 12/16/2020 | 57.11% | Barrington Research | → $43 | Upgrades | Market Perform → Outperform |
| 01/21/2020 | 122.87% | Sidoti & Co. | → $61 | Upgrades | Neutral → Buy |
| 11/05/2019 | 5.96% | BWS Financial | → $29 | Initiates Coverage On | → Sell |
| 09/23/2019 | — | First Analysis | Downgrades | Strong Buy → Outperform | |
| 02/22/2019 | 49.8% | Sidoti & Co. | $56 → $41 | Downgrades | Buy → Neutral |
| 07/27/2018 | — | Barrington Research | Upgrades | Market Perform → Outperform | |
| 06/20/2018 | 24.22% | First Analysis | $45 → $34 | Downgrades | Overweight → Equal-Weight |
| 05/04/2018 | — | Barrington Research | Upgrades | Market Perform → Outperform | |
| 02/23/2018 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 01/24/2018 | — | First Analysis | Upgrades | Equal-Weight → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2022 | 13.26% | 巴靈頓研究 | → 31 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 2022 年 10 月 14 日 | -5.01% | Stephens & Co. | → 26 美元 | 恢復 | → 重量相等 |
| 03/09/2022 | — | Stephens & Co. | 降級 | 超重 → 重量相等 | |
| 11/16/2021 | 100.95% | Stephens & Co. | → 55 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 07/16/2021 | 68.07% | 瑞銀（UBS） | → 46 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2020 年 12 月 16 日 | 57.11% | 巴靈頓研究 | → 43 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 2020 年 1 月 21 日 | 122.87% | Sidoti & Co. | → 61 美元 | 升級 | 中性 → 買入 |
| 11/05/2019 | 5.96% | BWS 金融 | → 29 美元 | 啓動覆蓋範圍開啓 | → 賣出 |
| 2019 年 9 月 23 日 | — | 第一次分析 | 降級 | 強勢買入 → 跑贏大盤 | |
| 02/22/2019 | 49.8% | Sidoti & Co. | 56 美元 → 41 美元 | 降級 | 買入 → 中性 |
| 07/27/2018 | — | 巴靈頓研究 | 升級 | 市場表現 → 跑贏大盤 | |
| 2018 年 6 月 20 日 | 24.22% | 第一次分析 | 45 美元 → 34 美元 | 降級 | 超重 → 重量相等 |
| 2018 年 4 月 5 日 | — | 巴靈頓研究 | 升級 | 市場表現 → 跑贏大盤 | |
| 02/23/2018 | — | 巴靈頓研究 | 降級 | 跑贏大盤 → 市場表現 | |
| 2018 年 1 月 24 日 | — | 第一次分析 | 升級 | 重量相等 → 超重 |
Anika Therapeutics Questions & Answers
Anika Therapeutics 問題與解答
The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on November 9, 2022. The analyst firm set a price target for $31.00 expecting ANIK to rise to within 12 months (a possible 13.26% upside). 4 analyst firms have reported ratings in the last year.
巴靈頓研究公司於2022年11月9日公佈了Anika Therapeutics（納斯達克股票代碼：ANIK）的最新目標股價。該分析公司將目標股價定爲31.00美元，預計ANIK將在12個月內升至12個月內（可能上漲13.26％）。去年有4家分析公司公佈了評級。
The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.
巴靈頓研究公司提供了Anika Therapeutics（納斯達克股票代碼：ANIK）的最新分析師評級，Anika Therapeutics上調了跑贏大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Anika Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Anika Therapeutics的最新評級是在2022年11月9日公佈的，因此您應該預計下一個評級將在2023年11月9日左右公佈。
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $31.00. The current price Anika Therapeutics (ANIK) is trading at is $27.37, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Anika Therapeutics（ANIK）評級已上調，目標股價爲0.00美元，至31.00美元。Anika Therapeutics（ANIK）目前的交易價格爲27.37美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。